ClinicalTrials.gg
CompletedNCT07937293Updated Nov 16, 2026

Association Between Intravenous Ferric Carboxymaltose Before Electrical Cardioversion and One-Year Atrial Fibrillation Recurrence in Patients With Heart Failure and Iron Deficiency

An observational study in Heart Failure and Atrial Fibrillation (AF), sponsored by Bursa Postgraduate Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Bursa Postgraduate Hospital · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
100
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Heart Failure with a site in Turkey — 27 open to participants now, 38 under way, 13 of them phase 3. Heart Failure · Turkey.

Enrollment
23rd of 44
100 · median 101
Started
2021
with 11 others
Observational
44 of 131
9 open now
Registered
131st of 131
by date
Lead sponsor
3 of 131
Bursa Postgraduate Hospital

Among the 131 studies in Heart Failure with a site in Turkey, this one is the 23rd largest by enrollment of the 44 observational ones that give a count, is one of 12 that started in 2021, is one of 44 observational ones, and was the 131st registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

27 of the 131 studies in Heart Failure with a site in Turkey are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Heart Failure with a site in Turkey, or all of them as a file.
02

Study summary

This study included 100 patients with persistent AF, heart failure (left ventricular ejection fraction 30-60%), and iron deficiency who underwent successful electrical cardioversion. Iron deficiency was defined as ferritin \<100 ng/mL or 100-299 ng/mL with transferrin saturation \<20%. Fifty patients received 1000 mg intravenous FCM immediately before cardioversion, while 50 served as controls. The primary endpoint was AF recurrence within 12 months.

03

Conditions studied

  • Heart Failure
  • Atrial Fibrillation (AF)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Heart failure and atrial fibrillation patients with iron deficiency.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients presenting to the cardiology clinic with atrial fibrillation (AF) for whom a rhythm-control strategy was selected and whose medical records contained complete clinical data.
  • Patients with persistent atrial fibrillation.
  • Patients aged 18-80 years.
  • Patients with levels \<13 g/dL in men or \<12 g/dL in women, and serum ferritin levels \<100 µg/L or ferritin levels of 100-300 µg/L with transferrin saturation (TSAT) \<20%.
  • Patients with a (LVEF) between 30% and 60%.
  • Patients who underwent successful electrical cardioversion.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of valvular heart surgery.
  • Patients with a \<30%.
  • Patients with rheumatological diseases.
  • Patients with severe valvular heart disease.
  • Patients with thyroid dysfunction.
  • Patients with a history of myocardial infarction within the preceding 3 months.
  • Patients with levels \<8 g/dL.
  • Patients who experienced an acute bleeding event within the preceding 3 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
100 participants (actual)
Patient registry
No

Interventions

  • DrugIV FCM

    intravenous ferric carboxymaltose (FCM) on atrial fibrillation (AF) recurrence following electrical cardioversion in patients with heart failure and iron deficiency .

06

What researchers measure

Primary outcomes

  1. Atrial Fibrillation Recurrence

    Time frame: one year

07

Study locations

1 site
  • Bursa Yüksek İhtisas
    Bursa, Turkey (Türkiye)
08

References and documents

Publications

  • 1. Hanna Rivero N, Tu SJ, Elliott AD, Pitman BM, Gallagher C, Lau DH, Sanders P, Wong CX. Anemia and iron deficiency in patients with atrial fibrillation. BMC Cardiovasc Disord. 2022;22:204. doi:10.1186/s12872-022-02646-5. 2. Mohamed AA, et al. Prognostic implications of iron deficiency in patients with heart failure. Heart. 2025;111:609 615. doi:10.1136/heartjnl-2024-324610. 3. Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S, et al. Intravenous iron for heart failure, iron deficiency definitions, and treatments. Eur J Heart Fail. 2023;25:528 537. doi:10.1002/ejhf.2947. 4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599 3726. doi:10.1093/eurheartj/ehab368. 5. Barutcu C, Kıvrak Z. Iron deficiency and anemia in heart failure: prevalence, prognosis and treatment. Turk J Health Sci Life. 2021;4(3):101 105.

Individual participant data

Plan to share: No — "Data will be made available upon reasonable request."

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Apr 2025, 51 months.

Of 796 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's 51 months is above that.

Counting every sponsor, half of 978 studies reached it within 41 months; a quarter within 22 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 16, 2026
StartActual
Jan 1, 2021
Primary completionActual
Apr 1, 2025
CompletionActual
Apr 1, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937293
Lead sponsor
Bursa Postgraduate Hospital
Responsible party
Hasan ARI (Prof Dr., Bursa Postgraduate Hospital) — Principal investigator
First posted
Nov 16, 2026
Start date
Jan 1, 2021
Primary completion
Apr 1, 2025
Completion
Apr 1, 2026
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion